Across TCGA pan-cancer cohorts, JAG2 mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated JAG2 data layer compared with 23 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher JAG2 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated JAG2 expression acts as an unfavorable survival marker, although some lineages such as GBM show a favorable association.

HNSC, GBM, and LSCC are the cancer types where JAG2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	OS	Quartile	II,III,IV	0.536	0.895	.019	16	view →
GBM	DFS	Tertile	All	0.907	0.579	.012	3	view →
LSCC	DFS	Quartile	All	0.295	0.755	.047	2	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

Exploration

Same gene, other analysis: JAG2 tumor-vs-normal RNA expression · all JAG2 data types